Key result
Rivaroxaban intake at 08:00 h increased ristocetin-induced platelet aggregation the next morning compared to no rivaroxaban (126 vs 109 AU; p=0.002).
Why the study?
Does rivaroxaban and diurnal variation affect platelet aggregation in healthy volunteers?
RCT (n=16)
Crossover
Does rivaroxaban and diurnal variation affect platelet aggregation in healthy volunteers?
Absolute Event Rate: 126% vs 109%
p-value: p=0.002
Ristocetin-induced platelet aggregation shows a diurnal rhythm peaking at noon, but is not influenced by selective Xa inhibition with rivaroxaban.
No takes yet. Share an insight, caveat, or question.
Morning rivaroxaban may alter next-day platelet reactivity; extends diurnal platelet data but leaves patient relevance open.
Schoergenhofer et al. (2015) conducted an RCT in Healthy volunteers (n=16). Rivaroxaban vs. No rivaroxaban was evaluated on Ristocetin-induced platelet aggregation (p=0.002). Rivaroxaban intake at 08:00 h increased ristocetin-induced platelet aggregation the next morning compared to no rivaroxaban (126 vs 109 AU; p=0.002).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: